Published: 1 September 2021
Archived: 21 August 2024
About Medsafe
COVID-19 Archive
Adverse events following immunisation with COVID-19 vaccines: Safety Report #24 – 14 August 2021
- Introduction
- Adverse events following immunisation (AEFI) reported
- Summary of reported deaths
- Adverse events of special interest
- Summary of safety signals
- Definitions
- More information
Introduction
This page provides information on the number of adverse events following immunisation (AEFI) reports received for COVID-19 vaccines.
An AEFI is an untoward medical event which follows immunisation and does not necessarily have a causal relationship with the administration of the vaccine. The adverse event may be an unfavourable or unintended sign, abnormal laboratory finding, symptom or disease.
The national roll-out of COVID-19 vaccines commenced on 20 February 2021. The vaccine currently available in New Zealand is Pfizer-BioNTech (Comirnaty). All medicines can cause side effects, the known side effects for Comirnaty are listed in the data sheet and consumer medicine information.
Suspected AEFI to COVID-19 vaccines are reported to the Centre for Adverse Reactions Monitoring (CARM). The Ministry of Health (through Medsafe) contracts the collection of this information to CARM, based at the University of Otago in Dunedin. Medsafe is closely monitoring the AEFI reported from the use of the COVID-19 vaccine. Find out more about vaccine safety monitoring.
Medsafe and CARM thank everyone who has contributed to the monitoring of COVID-19 vaccines. Please continue to report any adverse events following immunisation.
Adverse events following immunisation (AEFI) reported
The information below includes:
- AEFI reports received and vaccine doses administered
- AEFI reports by prioritised ethnicity and vaccine dose
- AEFI reports by age band and vaccine dose
- the top 10 most frequently reported AEFIs by vaccine dose.
AEFI reports received and vaccine doses administered, up to and including 14 August 2021
956
New AEFI reports since last update
(916 new non-serious and 40 new serious)
1
New safety signal (potential safety issue) has been identified
Guillain-Barré syndrome
2,483,436
Total doses administered
(cumulative)
9,688
Total AEFI reports that were non-serious
425
Total AEFI reports that were serious
10,113
Total AEFI reports that were received
(cumulative)
There were 916 non-serious and 40 serious reports this week. Sadly, five of these
serious reports reported on deaths.
The COVID-19 Vaccine Independent Safety Monitoring Board (CV-ISMB) has concluded its review into the death of a woman. The CV-ISMB considered the death was due to myocarditis, which is known to be a rare side effect of the Comirnaty vaccine.
The case has been referred to the Coroner and the cause of death has not yet been determined.
The CV-ISMB considered that the myocarditis was probably due to vaccination. The CV-ISMB noted that there were other medical issues occurring at the same time, which may have influenced the outcome following vaccination. The benefits of vaccination with the Comirnaty vaccine continue to greatly outweigh the risk of both COVID-19 infection and vaccine side effects, including myocarditis.
The Ministry has released a media statement and for more information about reported deaths, please refer to the summary of reported deaths section.
For information about safety signals, please refer to the summary of safety signals section.
AEFI reports received by prioritised ethnicity and vaccine dose, up to and including 14 August 2021
Ethnicitya | Dose 1 | Dose 2 | Total |
---|---|---|---|
Māori | 450 | 299 | 749 |
Pacific Peoples | 257 | 223 | 480 |
Asian | 856 | 593 | 1,449 |
European/Other | 4,145 | 3,111 | 7,256 |
Unknownb | 104 | 73 | 177 |
Total | 5,812 | 4,299 | 10,111c |
Notes:
- The prioritised ethnicity classification system allocates each person to a single ethnic group, based on the ethnic groups they identify with. Where people identify with more than one group, they are assigned in this order of priority: Māori, Pacific Peoples, Asian, and European/Other. So, if a person identifies as being Māori and New Zealand European, the person is counted as Māori. See Ethnicity Data Protocols for further information.
- There were 177 AEFI reports where the person’s ethnicity was not reported. Ethnicity is not required for an AEFI report to be considered valid. See ‘Valid report’ in the Definitions section below.
- The total is different from the cumulative total above because it excludes 2 AEFI reports received for infants who did not receive the vaccine (see safety report 10).
AEFI reports received by age band and vaccine dose, up to and including 14 August 2021
Age | Dose 1 | Dose 2 | Total |
---|---|---|---|
10 - 19 years | 154 | 64 | 218 |
20 - 29 years | 812 | 660 | 1,472 |
30 - 39 years | 941 | 798 | 1,739 |
40 - 49 years | 977 | 791 | 1,768 |
50 - 59 years | 1,048 | 789 | 1,837 |
60 - 69 years | 988 | 628 | 1,616 |
70 - 79 years | 602 | 392 | 994 |
80+ years | 283 | 171 | 454 |
Unknowna | 7 | 6 | 13 |
Total | 5,812 | 4,299 | 10,111b |
Note:
- There were 13 AEFI reports where the person’s age was not reported. Age is not required for an AEFI report to be considered valid. See ‘Valid report’ in the Definitions section below.
- The total is different from the cumulative total above because it excludes 2 AEFI reports received for infants who did not receive the vaccine (see safety report 10).
Top 10 most frequently reported AEFIs, any dose, up to and including 14 August 2021
Reaction | Number |
---|---|
Headache | 3,312 |
Dizziness | 2,966 |
Injection site pain | 2,485 |
Lethargy | 2,337 |
Nausea | 2,252 |
Fever | 1,552 |
Musculoskeletal pain | 999 |
Chest discomfort | 873 |
Numbness | 769 |
Feeling of body temperature change | 717 |
Top 10 most frequently reported AEFIs, dose 1 only, up to and including 14 August 2021
Reaction | Number |
---|---|
Dizziness | 1,842 |
Headache | 1,492 |
Injection site pain | 1,123 |
Nausea | 1,120 |
Lethargy | 984 |
Fever | 482 |
Chest discomfort | 463 |
Numbness | 455 |
Syncope (fainting) | 355 |
Musculoskeletal pain | 347 |
Top 10 most frequently reported AEFIs, dose 2 only, up to and including 14 August 2021
Reaction | Number |
---|---|
Headache | 1,820 |
Injection site pain | 1,362 |
Lethargy | 1,353 |
Nausea | 1,132 |
Dizziness | 1,124 |
Fever | 1,070 |
Musculoskeletal pain | 652 |
Feeling of body temperature change | 474 |
Chest discomfort | 410 |
Numbness | 314 |
Please note that one adverse event report, which represents one person,
may report on more than one symptom. Reports are sent to CARM if the reporter
suspects that the vaccine may have caused the event. This does not necessarily
mean that the vaccine did cause the event.
The number of reports can be influenced by how many people are being vaccinated, media attention, the nature of the events (eg, how painful the vaccination was), and other factors which vary over time. Not everyone who has an adverse reaction reports it, and some people may report AEFIs after each vaccination. The information here shows the number of reports not the number of people who experienced an AEFI.
The information is limited by the information provided in the report and may change over time due to quality control procedures and/or receipt of additional information. Non-valid reports are not included in the data.
Summary of reported deaths
Up to and including 14 August 2021, a total of 31 deaths were reported to CARM after the administration of the Comirnaty vaccine. Following medical assessments by CARM and Medsafe it has been determined that:
- 17 of these deaths are unlikely related to the COVID-19 vaccine
- 4 deaths could not be assessed due to insufficient information
- 9 cases are still under investigation.
- 1 death was likely due to vaccine induced myocarditis (awaiting Coroner’s determination)
By chance, some people will experience new illnesses or die from a pre-existing condition shortly after vaccination, especially if they are elderly. Therefore, part of our review process includes comparing natural death rates to observed death rates following vaccination, to determine if there are any specific trends or patterns that might indicate a vaccine safety concern.
To date, the observed number of deaths reported after vaccination is actually less than the expected number of natural deaths.
Mortalities by age group up to and including 14 August 2021
Age | Mortalities |
---|---|
10 - 29 years | 0 |
30 - 59 years | 6 |
60 - 79 years | 11 |
80+ years | 14 |
Adverse events of special interest
Adverse events of special interest (AESI) are pre-specified medically significant events that have the potential to be causally associated with the vaccine and must be carefully monitored. AESI can be serious or non-serious and can include:
- Events of interest due to their association with COVID-19 infection.
- Events of interest for vaccines in general (e.g. to the specific vaccine type or adjuvants).
The list of AESIs below takes into consideration the lists of AESIs from expert groups such as the Brighton Collaboration, manufacturers and other regulatory authorities. The AESI list changes based on the evolving safety profile of vaccines. It is important to note that although these adverse events may occur after being vaccinated with a COVID-19 vaccine in New Zealand, they are rare and may not necessarily be related to the vaccine. Medsafe and CARM review the reports to determine whether the vaccine may have played a role in the occurrence of these events.
Adverse events of special interest (AESI) up to and including 14 August 2021
AESI Category | AESI | Totala |
---|---|---|
Immune system disorders | Guillain-Barré Syndrome | <6 |
Thrombocytopenia | 7 | |
Thrombosis with thrombocytopenia syndrome (TTS) | 0 | |
Anaphylaxisb | 31 | |
Cardiovascular system | Myocardial infarction (heart attack) | 10 |
Myocarditis/pericarditis | 26 | |
Blood and lymphatic system | Thrombosis | 9 |
Embolism | 16 | |
Deep vein thrombosis (DVT) | 23 | |
Vasculitis | <6 | |
Haemorrhage | 39 | |
Hepato-gastrointestinal and renal system | Acute kidney injury | <6 |
Acute liver injury | <6 | |
Nervous system | Aseptic meningitis | 0 |
Encephalitis | 0 | |
Stroke | 25 | |
Bell's Palsy/facial paralysis | 37 | |
Myelitis | 0 | |
Infections and musculoskeletal | Erythema multiforme | <6 |
Arthritis | 8 | |
Herpes zoster | 57 | |
Pregnancy, puerperium and perinatal conditions | Abortion (spontaneous abortion /miscarriage) | <6 |
- Includes all reports, both serious and non-serious. Counts below 6 are reported as <6 for privacy reasons. Counts may change due to receipt of additional information and subsequent reclassification of cases.
- Includes reports meeting levels 1-3 of the Brighton Collaboration case definition.
Summary of safety signals
Summary of Medsafe’s investigations into possible safety signals
New safety signal: Guillain-Barré Syndrome
Medsafe has investigated a possible safety signal of Guillain-Barre Syndrome (GBS), based on cases (<6) reported to CARM. The data was presented to the CV-ISMB who concluded that it is difficult to assign causality to GBS cases for any vaccine but the onset time did not suggest a strong relationship to vaccination. The CV-ISMB further noted that there was not enough information to confirm that the cases reported to CARM were GBS. Medsafe will continue to monitor reported cases of GBS through the usual safety monitoring processes.
Ongoing monitoring: glomerular diseases
Medsafe has completed its investigation into glomerular diseases (diseases that affect the kidneys’ ability to balance certain substances in the blood). The data was presented to the CV-ISMB and there was consensus that there is no reason to suspect that the Comirnaty vaccine causes glomerular diseases as this stage. Medsafe will continue to monitor through the usual safety monitoring processes.
Ongoing monitoring: tinnitus
Medsafe has completed its investigation into tinnitus after receiving additional information from Pfizer. The data was presented to the CV-ISMB and it was concluded that there is currently not enough evidence to suspect that the Comirnaty vaccine causes tinnitus. Medsafe will continue to monitor reported events of tinnitus.
Safety signal | Outcome |
---|---|
Blood clots | Continue to monitor. See also the Monitoring communication |
Appendicitis | Continue to monitor |
Myocarditis/pericarditis | Information has been added to Comirnaty data sheet. See also the Alert communication |
Herpes zoster | Continue to monitor |
Bell’s palsy/facial paralysis | Continue to monitor |
Menstrual disorder | Continue to monitor |
Stroke | Continue to monitor |
Tinnitus | Continue to monitor |
AEFIs in the elderly | Continue to monitor and updated data sheet |
Pancreatitis | Continue to monitor |
Glomerular diseases | Continue to monitor |
Guillain-Barré Syndrome | Continue to monitor |
Definitions
- Adverse event following immunisation (AEFI)
- An AEFI is an untoward medical event which follows immunisation and does not necessarily have a causal relationship with the administration of the vaccine. The adverse event may be an unfavourable or unintended sign, abnormal laboratory finding, symptom or disease.
- Serious adverse event following immunisation
- An AEFI is considered serious if it:
- is a medically important event or reaction
- requires hospitalisation or prolongs an existing hospitalisation
- causes persistent or significant disability or incapacity
- is life threatening
- causes a congenital anomaly/birth defect
- results in death.
- Adverse events of special interest (AESI)
- An AESI is a pre-specified medically significant event that has the potential to be causally associated with the vaccine product based on past experience, the technology used to make the vaccine or the infection the vaccine is used to protect against. AESIs need to be carefully monitored and any potential association to vaccination confirmed by further analysis and studies.
- Safety signal
- Information on a new or known adverse event that may be caused by the vaccine and requires further investigation. Safety signals can be detected from a wide range of sources such as CARM reports, clinical studies and scientific literature.
- Valid report
- There are only four requirements for a valid AEFI report:
- one patient identifier (eg, name, initials, gender, date of birth, age)
- suspect medicine(s)
- suspected reaction(s)
- reporter details.
More information
See the data sheets and consumer medicine information for the expected reactions for approved COVID-19 vaccines.
COVID-19 Vaccine Safety Monitoring Process
View Ministry of Health COVID-19 vaccine data
Latest listing of all cases received
The latest listing of AEFIs received is included in the attached spreadsheet. Medsafe advises patients NOT to make any decisions about vaccination based on information contained here.